Welcome to our dedicated page for Ir-Med news (Ticker: IRME), a resource for investors and traders seeking the latest updates and insights on Ir-Med stock.
IR-MED Inc. (OTCQB: IRME) news centers on its development of noninvasive, AI-driven spectrographic and infrared spectroscopy platforms for pressure injury and diabetic foot ulcer assessment. The company’s updates highlight progress with its lead device, PressureSafe™, and its second product, DiaSafe™, along with clinical data, grants, and investor communications.
Readers following IRME news can find announcements on clinical and usability studies of PressureSafe™ in Israel and the United States, including work with Clalit medical centers and Methodist Healthcare in Texas. These reports describe sensitivity and specificity in detecting early-stage pressure injuries and discuss how the technology is being used across diverse skin tones to address longstanding disparities in skin assessment.
News releases also cover DiaSafe™, a handheld device under development for diabetic foot ulcer assessment. IR-MED has reported multiple grants from the Israel Innovation Authority to advance DiaSafe’s hardware, software and first-in-human clinical trials, emphasizing the scale and severity of diabetic foot ulcers as a global healthcare challenge.
In addition to clinical and product milestones, IR-MED’s news flow includes shareholder and investor update letters, participation in professional conferences, media features, and capital-raising activities disclosed through SEC filings. These items provide context on the company’s strategic priorities, financial condition and efforts toward commercialization of its platform technology.
For investors and healthcare professionals, the IRME news page offers a consolidated view of how the company’s AI and infrared-based decision support devices are progressing through studies, regulatory steps and funding events. Regularly reviewing this coverage can help track key developments in IR-MED’s pressure injury and diabetic foot ulcer programs.
IR-MED has published positive results from a usability study of its PressureSafe™ device, performed in collaboration with Clalit, Israel's largest HMO. The study, which included 924 scans on 154 body locations, demonstrated that PressureSafe™ could reduce pressure injuries by 50%. The device achieved 92% sensitivity and 88% specificity in detecting Stage 1 and suspected deep tissue injury pressure injuries. PressureSafe™, which uses AI-driven infra-red spectroscopy, has received FDA listing confirmation. The findings were also presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.